UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2023

 

Commission File Number: 001-41316

 

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒             Form 40-F

  

 

 

 

 

CONTENTS

 

The following documents are attached hereto and incorporated by reference herein:

 

Exhibit 99.1. Interim Consolidated Financial Statements as of June 30, 2023.

 

Exhibit 99.2. Operating and Financial Review and Prospects in connection the Interim Consolidated Financial Statements for the six months ended June 30, 2023.

 

The Interim Consolidated Financial Statements of Alpha Tau Medical Ltd. as of June 30, 2023 attached as Exhibit 99.1 and the Operating Results and Financial Review in connection with the Interim Consolidated Financial Statements of Alpha Tau Medical Ltd. for the six months ended June 30, 2023 attached as Exhibit 99.2 to this Report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-271073 and 333-264306) and Form S-8 (File Nos. 333-270406 and 333-264169).

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Interim Consolidated Financial Statements as of June 30, 2023.
     
99.2   Operating and Financial Review and Prospects in connection the Interim Consolidated Financial Statements for the six months ended June 30, 2023.
     
101   The following financial information from Alpha Tau Medical Ltd.’s Report on Form 6-K, formatted in XBRL (eXtensible Business Reporting Language): (i) Interim Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022; (ii) Interim Consolidated Statements of Operations for the six months ended June 30, 2022 and 2022; (iii) Interim Consolidated Statements of Changes in Shareholders’ Equity for the six months ended June 30, 2023 and 2022; (iv) Interim Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022; and (v) Notes to the Interim Consolidated Financial Statements.
104   Cover Page Interactive Data File (embedded within the inline XBRL document).

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALPHA TAU MEDICAL LTD.
     
Date: August 28, 2023 By: /s/ Uzi Sofer
    Uzi Sofer
    Chief Executive Officer

 

 

3